5-[(1R)-1-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl)ethyl]-1H-1,2,4-triazol-1-ol | 1144016-11-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-[(1R)-1-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl)ethyl]-1H-1,2,4-triazol-1-ol
• 英文别名: N-[4-[(1R)-1-(2-hydroxy-1,2,4-triazol-3-yl)ethyl]phenyl]-4-(trifluoromethyl)-1,3-thiazol-2-amine
• CAS: 1144016-11-4
• 化学式: C₁₄H₁₂F₃N₅OS
• 分子量: 355.343
• InChiKey: NZXOOPPMMVMGAQ-MRVPVSSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  N-{4-[(1R)-1-(1H-1,2,4-triazol-5-yl)ethyl]phenyl}-4-(trifluoromethyl)-1,3-thiazol-2-amine 在 间氯过氧苯甲酸 作用下， 以 乙酸乙酯 为溶剂， 以67%的产率得到5-[(1R)-1-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl)ethyl]-1H-1,2,4-triazol-1-ol
  参考文献：
  名称：

  [EN] (R)-4-(HETEROARYL) PHENYLETHYL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  [FR] DÉRIVÉS DE (R)-4-(HÉTÉROARYL)PHÉNYLÉTHYLE ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT

  摘要：

  本发明涉及一类新型的(R)-4-(杂环)苯丙酸衍生物，其化学式为(I)，用于抑制由补体C5a分子引起的趋化活化。所述化合物在治疗依赖于补体C5a分子引起的中性粒细胞和单核细胞趋化活化的病理方面具有用处。具体而言，本发明的化合物在治疗自身免疫性溶血性贫血（AIHA）、银屑病、大疱性类天疱疮、类风湿性关节炎、溃疡性结肠炎、急性呼吸窘迫综合征、特发性纤维化、肾小球肾炎以及缺血再灌注所致损伤的预防和治疗方面具有用处。

  公开号：

  WO2009050258A1

文献信息

• (R)-4-(HETEROARYL) PHENYLETHYL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Moriconi Alessio

  公开号：US20100249198A1

  公开（公告）日：2010-09-30

  The present invention relates to a novel class of (R)-4-(heteroaryl)phenylpropionic derivatives of formula (I), useful in the inhibition of the chemotactic activation induced by the fraction C5a of complement. Said compounds are useful in the treatment of pathologies depending on the chemotactic activation of neutrophils and monocytes induced by the fraction C5a of the complement. In particular, the compounds of the invention are useful in the treatment of autoimmune hemolytic anemia (AIHA), psoriasis, bullous pemphigoid, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of injury caused by ischemia and reperfusion.

  本发明涉及一种新型的(R)-4-(杂环芳基)苯丙酸衍生物，化学式为(I)，其可用于抑制补体C5a分子诱导的趋化激活。该类化合物可用于治疗依赖于补体C5a分子诱导的中性粒细胞和单核细胞趋化激活的病理学。特别是，该发明的化合物可用于治疗自身免疫性溶血性贫血（AIHA）、银屑病、大疱性类天疱疮、类风湿性关节炎、溃疡性结肠炎、急性呼吸窘迫综合征、特发性纤维化、肾小球肾炎以及缺血再灌注引起的损伤的预防和治疗。
• (R)-4-(heteroaryl) phenylethyl derivatives and pharmaceutical compositions containing them
  申请人：Dompe S.p.A

  公开号：US08133911B2

  公开（公告）日：2012-03-13

  The present invention relates to a novel class of (R)-4-(heteroaryl)phenylpropionic derivatives of formula (I), useful in the inhibition of the chemotactic activation induced by the fraction C5a of complement. Said compounds are useful in the treatment of pathologies depending on the chemotactic activation of neutrophils and monocytes induced by the fraction C5a of the complement. In particular, the compounds of the invention are useful in the treatment of autoimmune hemolytic anemia (AIHA), psoriasis, bullous pemphigoid, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of injury caused by ischemia and reperfusion.

  本发明涉及一类新型的(R)-4-(杂环芳基)苯丙酸衍生物，化学式为(I)，用于抑制补体C5a分子诱导的趋化活化。该类化合物在治疗由于补体C5a分子诱导的中性粒细胞和单核细胞趋化活化所引起的病理状况方面具有用途。特别地，本发明的化合物在治疗自身免疫性溶血性贫血（AIHA）、银屑病、大疱性类天疱疮、类风湿性关节炎、溃疡性结肠炎、急性呼吸窘迫综合症、特发性纤维化、肾小球肾炎以及缺血再灌注所致损伤的预防和治疗方面具有用途。
• C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN
  申请人：Dompé farmaceutici S.p.A.

  公开号：EP3498269A1

  公开（公告）日：2019-06-19

  The present invention relates to C5aR inhibitor compounds, preferably C5aR noncompetitive allosteric inhibitors, useful in the treatment and/or prevention of chemotherapy-induced iatrogenic pain (CIIP).

  本发明涉及C5aR抑制剂化合物，最好是C5aR非竞争性异位抑制剂，可用于治疗和/或预防化疗引起的先天性疼痛（CIIP）。
• US8133911B2
  申请人：——

  公开号：US8133911B2

  公开（公告）日：2012-03-13
• [EN] (R)-4-(HETEROARYL) PHENYLETHYL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] DÉRIVÉS DE (R)-4-(HÉTÉROARYL)PHÉNYLÉTHYLE ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：DOMPE SPA

  公开号：WO2009050258A1

  公开（公告）日：2009-04-23

  The present invention relates to a novel class of (R)-4-(heteroaryl)phenylpropionic derivatives of formula (I), useful in the inhibition of the chemotactic activation induced by the fraction C5a of complement. Said compounds are useful in the treatment of pathologies depending on the chemotactic activation of neutrophils and monocytes induced by the fraction C5a of the complement. In particular, the compounds of the invention are useful in the treatment of autoimmune hemolytic anemia (AIHA), psoriasis, bullous pemphigoid, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of injury caused by ischemia and reperfusion.

  本发明涉及一类新型的(R)-4-(杂环)苯丙酸衍生物，其化学式为(I)，用于抑制由补体C5a分子引起的趋化活化。所述化合物在治疗依赖于补体C5a分子引起的中性粒细胞和单核细胞趋化活化的病理方面具有用处。具体而言，本发明的化合物在治疗自身免疫性溶血性贫血（AIHA）、银屑病、大疱性类天疱疮、类风湿性关节炎、溃疡性结肠炎、急性呼吸窘迫综合征、特发性纤维化、肾小球肾炎以及缺血再灌注所致损伤的预防和治疗方面具有用处。